
Pyelonephritis - Pipeline Insight, 2025
Description
DelveInsight’s, “Pyelonephritis- Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pyelonephritis: Overview
Pyelonephritis is a type of urinary tract infection (UTI) that affects one or both kidneys. It is typically caused by bacteria that travel from the bladder up to the kidneys. This condition can be acute, meaning it occurs suddenly, or chronic, indicating long-term kidney infection or repeated episodes of acute pyelonephritis. If left untreated, pyelonephritis can lead to serious complications, including kidney damage, sepsis, and chronic kidney disease. The signs and symptoms of pyelonephritis often include fever, chills, flank pain (pain in the sides and back), nausea, vomiting, and frequent, painful urination. Patients may also experience symptoms typical of lower UTIs, such as urgency to urinate and cloudy or foul-smelling urine. In severe cases, there may be blood in the urine (hematuria). It's crucial for individuals experiencing these symptoms to seek medical attention promptly, as the infection can spread quickly to the bloodstream, leading to sepsis.
The primary cause of pyelonephritis is bacterial infection, most commonly by Escherichia coli (E. coli), which is normally found in the intestines. Other bacteria, such as Klebsiella, Proteus, and Enterobacter species, can also cause the infection. Risk factors include a history of UTIs, structural abnormalities in the urinary tract, urinary catheter use, and conditions that impair the immune system, such as diabetes. Women are more prone to pyelonephritis due to their shorter urethra, which facilitates the ascent of bacteria to the bladder and kidneys. Pathophysiologically, pyelonephritis involves the bacteria ascending from the lower urinary tract to the kidneys, triggering an inflammatory response. The infection can cause the renal parenchyma (the functional tissue of the kidney) to become inflamed, which can lead to abscess formation and scarring. Chronic pyelonephritis often results from repeated infections or ongoing obstruction in the urinary tract, leading to progressive kidney damage and loss of renal function over time.
Diagnosis of pyelonephritis is based on clinical presentation, laboratory tests, and imaging studies. Urinalysis typically reveals the presence of white blood cells, bacteria, and sometimes red blood cells. Urine culture is performed to identify the causative organism and determine its antibiotic sensitivity. Blood tests may show elevated white blood cell counts and markers of inflammation. Imaging studies, such as ultrasound or CT scans, can be useful to assess the kidneys for abscesses, stones, or structural abnormalities. Treatment involves prompt initiation of antibiotics, with the choice of medication guided by the severity of the infection and the results of the urine culture. In severe cases, hospitalization and intravenous antibiotics may be required. Supportive care, including pain management and hydration, is also important. Chronic or recurrent pyelonephritis may necessitate further investigation and management of underlying conditions to prevent future infections.
”Pyelonephritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyelonephritis pipeline landscape is provided which includes the disease overview and Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pyelonephritis Emerging Drugs
Further product details are provided in the report……..
Pyelonephritis: Therapeutic Assessment
This segment of the report provides insights about the different Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:
Pyelonephritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyelonephritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyelonephritis drugs.
Pyelonephritis Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Pyelonephritis: Overview
Pyelonephritis is a type of urinary tract infection (UTI) that affects one or both kidneys. It is typically caused by bacteria that travel from the bladder up to the kidneys. This condition can be acute, meaning it occurs suddenly, or chronic, indicating long-term kidney infection or repeated episodes of acute pyelonephritis. If left untreated, pyelonephritis can lead to serious complications, including kidney damage, sepsis, and chronic kidney disease. The signs and symptoms of pyelonephritis often include fever, chills, flank pain (pain in the sides and back), nausea, vomiting, and frequent, painful urination. Patients may also experience symptoms typical of lower UTIs, such as urgency to urinate and cloudy or foul-smelling urine. In severe cases, there may be blood in the urine (hematuria). It's crucial for individuals experiencing these symptoms to seek medical attention promptly, as the infection can spread quickly to the bloodstream, leading to sepsis.
The primary cause of pyelonephritis is bacterial infection, most commonly by Escherichia coli (E. coli), which is normally found in the intestines. Other bacteria, such as Klebsiella, Proteus, and Enterobacter species, can also cause the infection. Risk factors include a history of UTIs, structural abnormalities in the urinary tract, urinary catheter use, and conditions that impair the immune system, such as diabetes. Women are more prone to pyelonephritis due to their shorter urethra, which facilitates the ascent of bacteria to the bladder and kidneys. Pathophysiologically, pyelonephritis involves the bacteria ascending from the lower urinary tract to the kidneys, triggering an inflammatory response. The infection can cause the renal parenchyma (the functional tissue of the kidney) to become inflamed, which can lead to abscess formation and scarring. Chronic pyelonephritis often results from repeated infections or ongoing obstruction in the urinary tract, leading to progressive kidney damage and loss of renal function over time.
Diagnosis of pyelonephritis is based on clinical presentation, laboratory tests, and imaging studies. Urinalysis typically reveals the presence of white blood cells, bacteria, and sometimes red blood cells. Urine culture is performed to identify the causative organism and determine its antibiotic sensitivity. Blood tests may show elevated white blood cell counts and markers of inflammation. Imaging studies, such as ultrasound or CT scans, can be useful to assess the kidneys for abscesses, stones, or structural abnormalities. Treatment involves prompt initiation of antibiotics, with the choice of medication guided by the severity of the infection and the results of the urine culture. In severe cases, hospitalization and intravenous antibiotics may be required. Supportive care, including pain management and hydration, is also important. Chronic or recurrent pyelonephritis may necessitate further investigation and management of underlying conditions to prevent future infections.
”Pyelonephritis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyelonephritis pipeline landscape is provided which includes the disease overview and Pyelonephritis treatment guidelines. The assessment part of the report embraces, in depth Pyelonephritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyelonephritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Pyelonephritis.
This segment of the Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pyelonephritis Emerging Drugs
- WCK 4282: Wockhardt
- Finafloxacin: MerLion Pharmaceuticals GmbH
Further product details are provided in the report……..
Pyelonephritis: Therapeutic Assessment
This segment of the report provides insights about the different Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pyelonephritis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Pyelonephritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyelonephritis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyelonephritis drugs.
Pyelonephritis Report Insights
- Pyelonephritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pyelonephritis drugs?
- How many Pyelonephritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyelonephritis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pyelonephritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pyelonephritis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Wockhardt
- MerLion Pharmaceuticals GmbH
- Spero Therapeutics
- Pfizer
- WCK 4282
- Finafloxacin
- Tebipenem HBr
- PF-07612577
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Pyelonephritis: Overview
- Introduction
- Causes
- Pathophysiology
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pyelonephritis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- WCK 4282: Wockhardt
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Finafloxacin: MerLion Pharmaceuticals GmbH
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pyelonephritis Key Companies
- Pyelonephritis Key Products
- Pyelonephritis- Unmet Needs
- Pyelonephritis- Market Drivers and Barriers
- Pyelonephritis- Future Perspectives and Conclusion
- Pyelonephritis Analyst Views
- Pyelonephritis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.